Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts

Fig. 3

Impact of U2AF1a–b and SRSF2c–d mutations on the clinical outcome of the MDS subgroups. Overall survival a and progression-free survival b–c are affected by U2AF1 or SRSF2 genotypes according to subgroup analysis of MDS patients. The probability of AML progression was increased for RCUD and RCMD patients with a mutation in SRSF2d. AML, acute myeloid leukemia; IPSS-R, revised International Prognostic Scoring System; mut, mutant; RAEB, refractory anemia with excess blasts; RCMD, refractory cytopenia with multilineage dysplasia; RCUD, refractory cytopenia with unilineage dysplasia; wt, wild-type

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us